Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $96.57, for a total value of $1,448,550.00. Following the completion of the sale, the chief executive officer now directly owns 190,207 shares of the company’s stock, valued at approximately $18,368,289.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Loxo Oncology Inc (NASDAQ:LOXO) traded up $3.43 during mid-day trading on Wednesday, hitting $104.35. The stock had a trading volume of 504,068 shares, compared to its average volume of 344,973. Loxo Oncology Inc has a 52 week low of $40.01 and a 52 week high of $108.50. The company has a market capitalization of $2,812.33, a price-to-earnings ratio of -17.31 and a beta of 2.57.
A number of brokerages have commented on LOXO. BidaskClub raised Loxo Oncology from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Zacks Investment Research raised Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. William Blair began coverage on Loxo Oncology in a research note on Tuesday, November 28th. They issued an “outperform” rating for the company. Citigroup reduced their price objective on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. Finally, JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their target price for the company from $77.18 to $95.00 in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $97.33.
COPYRIGHT VIOLATION WARNING: “Loxo Oncology Inc (LOXO) CEO Sells $1,448,550.00 in Stock” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/loxo-oncology-inc-loxo-ceo-sells-1448550-00-in-stock.html.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.